Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0386 Transporter Info
Gene Name	SLC4A5
Transporter Name	Electrogenic sodium bicarbonate cotransporter 4
Gene ID	57835
UniProt ID	Q9BY07

Post-Translational Modification of This DT
Overview ofSLC4A5 Modification Sites with Functional and Structural Information
Sequence	M K V K E E K A G V G K L D H T N H R R R F P D Q K E C P P I H I G L P V P T Y P Q R K T D Q K G H L S G L Q K V H W G L R P D Q P Q Q E L T G P G S G A S S Q D S S M D L I S R T R S P A A E Q L Q D I L G E E D E A P N P T L F T E M D T L Q H D G D Q M E W K E S A R W I K F E E K V E E G G E R W S K P H V S T L S L H S L F E L R T C L Q T G T V L L D L D S G S L P Q I I D D V I E K Q I E D G L L R P E L R E R V S Y V L L R R H R H Q T K K P I H R S L A D I G K S V S T T N R S P A R S P G A G P S L H H S T E D L R M R Q S A N Y G R L C H A Q S R S M N D I S L T P N T D Q R K N K F M K K I P K D S E A S N V L V G E V D F L D Q P F I A F V R L I Q S A M L G G V T E V P V P T R F L F I L L G P S G R A K S Y N E I G R A I A T L M V D D L F S D V A Y K A R N R E D L I A G I D E F L D E V I V L P P G E W D P N I R I E P P K K V P S A D K R K S V F S L A E L G Q M N G S V G G G G G A P G G G N G G G G G G G S G G G A G S G G A G G T S S G D D G E M P A M H E I G E E L I W T G R F F G G L C L D I K R K L P W F P S D F Y D G F H I Q S I S A I L F I Y L G C I T N A I T F G G L L G D A T D N Y Q G V M E S F L G T A M A G S L F C L F S G Q P L I I L S S T G P I L I F E K L L F D F S K G N G L D Y M E F R L W I G L H S A V Q C L I L V A T D A S F I I K Y I T R F T E E G F S T L I S F I F I Y D A I K K M I G A F K Y Y P I N M D F K P N F I T T Y K C E C V A P D T V N T T V F N A S A P L A P D T N A S L Y N L L N L T A L D W S L L S K K E C L S Y G G R L L G N S C K F I P D L A L M S F I L F F G T Y S M T L T L K K F K F S R Y F P T K V R A L V A D F S I V F S I L M F C G I D A C F G L E T P K L H V P S V I K P T R P D R G W F V A P F G K N P W W V Y P A S I L P A L L V T I L I F M D Q Q I T A V I V N R K E N K L K K A A G Y H L D L F W V G I L M A L C S F M G L P W Y V A A T V I S I A H I D S L K M E T E T S A P G E Q P Q F L G V R E Q R V T G I I V F I L T G I S V F L A P I L K C I P L P V L Y G V F L Y M G V A S L N G I Q M G T G G S E F K I Q K K L T P F W E R C K L F L M P A K H Q P D H A F L R H V P L R R I H L F T L V Q I L C L A V L W I L K S T V A A I I F P V M I L G L I I V R R L L D F I F S Q H D L A W I D N I L P E K E K K E T D K K R K R K K G A H E D C D E E P Q F P P P S V I K I P M E S V Q S D P Q N G I H C I A R K R S S S W S Y S L
PTM type	X-Phosphorylation X-Ubiquitination X: Amino Acid

Phosphorylation
Serine	6 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC4A5			[1], [2]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	227
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Serine 227 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC4A5			[3]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	251
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Serine 251 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC4A5			[3]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	255
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Serine 255 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC4A5			[4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	438
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Serine 438 has the potential to affect its expression or activity.
PTM Phenomenon5	Have the potential to influence SLC4A5			[4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	458
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Serine 458 has the potential to affect its expression or activity.
PTM Phenomenon6	Have the potential to influence SLC4A5			[5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	718
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Serine 718 has the potential to affect its expression or activity.
Threonine	3 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC4A5			[3]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	256
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Threonine 256 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC4A5			[6]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	335
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Threonine 335 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC4A5			[6]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	341
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Threonine 341 has the potential to affect its expression or activity.
Tyrosine	3 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC4A5			[7], [8]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	357
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Tyrosine 357 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC4A5			[7], [8]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	378
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Tyrosine 378 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC4A5			[7], [8]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	677
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC4A5 Tyrosine 677 has the potential to affect its expression or activity.
Ubiquitination
Lysine	5 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	.			[9]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	773
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC4A5 Lysine 773 has the potential to affect its expression or activity.
PTM Phenomenon2	.			[9]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	773
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC4A5 Lysine 773 has the potential to affect its expression or activity.
PTM Phenomenon3	.			[9]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	773
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC4A5 Lysine 773 has the potential to affect its expression or activity.
PTM Phenomenon4	.			[9]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	773
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC4A5 Lysine 773 has the potential to affect its expression or activity.
PTM Phenomenon5	.			[9]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	773
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC4A5 Lysine 773 has the potential to affect its expression or activity.

References
1	Modulation of Cl- signaling and ion transport by recruitment of kinases and phosphatases mediated by the regulatory protein IRBIT. Sci Signal. 2018 Oct 30;11(554):eaat5018.
2	Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab. Neoplasia. 2018 Jul;20(7):668-677.
3	Comparison of SILAC and mTRAQ quantification for phosphoproteomics on a quadrupole orbitrap mass spectrometer. J Proteome Res. 2013 Sep 6;12(9):4089-100.
4	An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62.
5	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
6	iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012 Jun;11(6):M111.014423.
7	Systematic functional prioritization of protein posttranslational modifications. Cell. 2012 Jul 20;150(2):413-25.
8	Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007 Dec 14;131(6):1190-203.
9	ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins. Nucleic Acids Res. 2018;46(D1):D901-D910.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence